Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 635

1.

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Int Clin Psychopharmacol. 2008 Nov;23(6):325-31. doi: 10.1097/YIC.0b013e32830c2042.

PMID:
18854720
2.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
3.

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O.

J Clin Psychiatry. 2003 Oct;64(10):1250-7.

PMID:
14658976
5.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
6.

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M.

J Clin Psychiatry. 2004 Apr;65(4):531-6. Erratum in: J Clin Psychiatry. 2004 Aug;65(8):1150.

PMID:
15119916
7.

Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.

Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.

Eur Psychiatry. 2010 May;25(4):220-9. doi: 10.1016/j.eurpsy.2009.09.001. Epub 2009 Nov 18.

PMID:
19926263
8.

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.

Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG; Risperidone Long-Acting Trial Investigators (R-LAI).

Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.

PMID:
19790173
9.
10.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
11.

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM.

J Clin Psychiatry. 2006 Aug;67(8):1194-203.

PMID:
16965196
12.

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia.

J Clin Psychiatry. 2007 Nov;68(11):1763-74.

PMID:
18052570
13.
14.

Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.

Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM.

Ann Clin Psychiatry. 2007 Apr-Jun;19(2):65-71.

PMID:
17612845
15.

Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.

Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq ZU, Saleh BT.

Curr Med Res Opin. 2003;19(4):298-305.

PMID:
12841922
16.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
17.

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.

Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.

Pharmacopsychiatry. 2007 Nov;40(6):257-63.

PMID:
18030649
18.

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.

Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.

Hum Psychopharmacol. 2010 Jan;25(1):37-46. doi: 10.1002/hup.1085.

PMID:
20041474
19.

Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.

Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.

J Med Assoc Thai. 2010 Mar;93(3):343-50.

PMID:
20420110
20.

The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.

Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G.

J Nerv Ment Dis. 2007 Dec;195(12):976-82.

PMID:
18091190

Supplemental Content

Support Center